Raymond James Financial Services Advisors Inc. boosted its position in Voyager Therapeutics Inc (NASDAQ:VYGR) by 2.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 183,201 shares of the company’s stock after purchasing an additional 3,930 shares during the period. Raymond James Financial Services Advisors Inc. owned about 0.56% of Voyager Therapeutics worth $1,722,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Voyager Therapeutics by 66.8% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,380 shares of the company’s stock valued at $101,000 after acquiring an additional 4,559 shares during the period. AlphaCrest Capital Management LLC bought a new position in Voyager Therapeutics in the 4th quarter valued at about $102,000. Nisa Investment Advisors LLC raised its holdings in Voyager Therapeutics by 24.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 12,800 shares of the company’s stock valued at $120,000 after acquiring an additional 2,500 shares during the period. Man Group plc bought a new position in Voyager Therapeutics in the 3rd quarter valued at about $245,000. Finally, Rhumbline Advisers raised its holdings in Voyager Therapeutics by 48.1% in the 4th quarter. Rhumbline Advisers now owns 27,989 shares of the company’s stock valued at $263,000 after acquiring an additional 9,086 shares during the period. Institutional investors and hedge funds own 85.37% of the company’s stock.

In other Voyager Therapeutics news, major shareholder Neurocrine Biosciences Inc bought 4,179,728 shares of the stock in a transaction dated Tuesday, March 12th. The shares were bought at an average cost of $11.96 per share, with a total value of $49,989,546.88. Following the completion of the acquisition, the insider now owns 4,179,728 shares of the company’s stock, valued at $49,989,546.88. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 33.60% of the stock is currently owned by company insiders.

Several research firms have weighed in on VYGR. ValuEngine raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. Cantor Fitzgerald began coverage on shares of Voyager Therapeutics in a report on Tuesday, March 5th. They issued an “overweight” rating and a $27.00 price target on the stock. BidaskClub raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 6th. Zacks Investment Research raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Saturday, March 2nd. Finally, Cowen reissued a “buy” rating on shares of Voyager Therapeutics in a report on Wednesday, February 27th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $24.00.

Shares of VYGR opened at $19.66 on Friday. Voyager Therapeutics Inc has a 12 month low of $7.76 and a 12 month high of $24.24. The company has a market cap of $641.25 million, a PE ratio of -7.15 and a beta of 2.77.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, February 26th. The company reported ($0.70) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.70). Voyager Therapeutics had a negative net margin of 1,158.79% and a negative return on equity of 120.82%. On average, research analysts predict that Voyager Therapeutics Inc will post -2.93 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Voyager Therapeutics Inc (VYGR) Position Raised by Raymond James Financial Services Advisors Inc.” was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.mareainformativa.com/news/2019/03/17/voyager-therapeutics-inc-vygr-position-raised-by-raymond-james-financial-services-advisors-inc.html.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Article: Earnings Per Share (EPS)

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.